The International Consortium to Advance Clinical Trials for Prader-Willi Syndrome (PWS-CTC) was established in 2015 to encourage collaboration and leverage the expertise and perspective of stakeholders from industry, academia, and patient organizations in a pre-competitive space in order to address the unmet scientific, technical, clinical and regulatory needs of clinical trials for PWS.
The Consortium aims to develop outcome measures to assess treatment efficacy against hyperphagia and other behavioral challenges, as well as develop rigorous methods to incorporate the patient and caregiver perspectives into the benefit/risk assessment of new treatments.
NEW 5-MINUTE VIDEO AVAILABLE: What is Prader-Willi Syndrome. Watch the video >>
PWS-CTC recently attended a Critical Path Innovation Meeting (CPIM) with representatives of the FDA. This unique opportunity allowed the PWS consortium to engage in discussions with the FDA on the progress made in the last three years by the consortium to overcome clinical trial challenges in PWS. Read more >>
Read the latest publication from the PWS-CTC: High Levels of Caregiver Burden in Prader-Willi Syndrome, in PlosOne. Read here >>
Learn more about the complexity and challenges of PWS on the individual with PWS and their families in our video: PWS Across the Lifespan. Watch Video >>